Cargando…

Recent Advances in Combined Modality Therapy

Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways...

Descripción completa

Detalles Bibliográficos
Autores principales: Mierzwa, Michelle L., Nyati, Mukesh K., Morgan, Meredith A., Lawrence, Theodore S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227964/
https://www.ncbi.nlm.nih.gov/pubmed/20413642
http://dx.doi.org/10.1634/theoncologist.2009-S105
_version_ 1782217795778379776
author Mierzwa, Michelle L.
Nyati, Mukesh K.
Morgan, Meredith A.
Lawrence, Theodore S.
author_facet Mierzwa, Michelle L.
Nyati, Mukesh K.
Morgan, Meredith A.
Lawrence, Theodore S.
author_sort Mierzwa, Michelle L.
collection PubMed
description Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways involved in tumor growth and immortality have resulted in the development of biologically targeted drugs. This review highlights the recent clinical data in support of newer generation cytotoxic chemotherapies and systemic targeted agents in combination with radiation therapy.
format Online
Article
Text
id pubmed-3227964
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-32279642012-04-25 Recent Advances in Combined Modality Therapy Mierzwa, Michelle L. Nyati, Mukesh K. Morgan, Meredith A. Lawrence, Theodore S. Oncologist New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein Combined modality therapy emerged from preclinical data showing that carefully chosen drugs could enhance the sensitivity of tumor cells to radiation while having nonoverlapping toxicities. Recent advances in molecular biology involving the identification of cellular receptors, enzymes, and pathways involved in tumor growth and immortality have resulted in the development of biologically targeted drugs. This review highlights the recent clinical data in support of newer generation cytotoxic chemotherapies and systemic targeted agents in combination with radiation therapy. AlphaMed Press 2010-04 /pmc/articles/PMC3227964/ /pubmed/20413642 http://dx.doi.org/10.1634/theoncologist.2009-S105 Text en ©AlphaMed Press available online without subscription through the open access option.
spellingShingle New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein
Mierzwa, Michelle L.
Nyati, Mukesh K.
Morgan, Meredith A.
Lawrence, Theodore S.
Recent Advances in Combined Modality Therapy
title Recent Advances in Combined Modality Therapy
title_full Recent Advances in Combined Modality Therapy
title_fullStr Recent Advances in Combined Modality Therapy
title_full_unstemmed Recent Advances in Combined Modality Therapy
title_short Recent Advances in Combined Modality Therapy
title_sort recent advances in combined modality therapy
topic New Translational Research in Radiation Oncology: A Tribute to Eli Glatstein
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227964/
https://www.ncbi.nlm.nih.gov/pubmed/20413642
http://dx.doi.org/10.1634/theoncologist.2009-S105
work_keys_str_mv AT mierzwamichellel recentadvancesincombinedmodalitytherapy
AT nyatimukeshk recentadvancesincombinedmodalitytherapy
AT morganmereditha recentadvancesincombinedmodalitytherapy
AT lawrencetheodores recentadvancesincombinedmodalitytherapy